CN1745099A - 修饰的可溶性t细胞受体 - Google Patents
修饰的可溶性t细胞受体 Download PDFInfo
- Publication number
- CN1745099A CN1745099A CNA03826014XA CN03826014A CN1745099A CN 1745099 A CN1745099 A CN 1745099A CN A03826014X A CNA03826014X A CN A03826014XA CN 03826014 A CN03826014 A CN 03826014A CN 1745099 A CN1745099 A CN 1745099A
- Authority
- CN
- China
- Prior art keywords
- tcr
- stcr
- chain
- mixture
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Jellies, Jams, And Syrups (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
TCRα链 | TCRβ链 | 天然β碳原子间隔(nm) |
Thr 48Thr 45Tyr 10Thr 45Ser 15 | Ser 57Ser 77Ser 17Asp 59Glu 15 | 0.4730.5330.3590.5600.59 |
Claims (34)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0304068.0A GB0304068D0 (en) | 2003-02-22 | 2003-02-22 | Substances |
GB0304068.0 | 2003-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1745099A true CN1745099A (zh) | 2006-03-08 |
CN100528897C CN100528897C (zh) | 2009-08-19 |
Family
ID=9953480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03826014XA Expired - Lifetime CN100528897C (zh) | 2003-02-22 | 2003-07-09 | 修饰的可溶性t细胞受体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7666604B2 (zh) |
EP (1) | EP1594896B1 (zh) |
JP (1) | JP4478034B2 (zh) |
CN (1) | CN100528897C (zh) |
AT (1) | ATE388964T1 (zh) |
AU (1) | AU2003254443B2 (zh) |
CA (1) | CA2516702C (zh) |
DE (1) | DE60319745T2 (zh) |
GB (1) | GB0304068D0 (zh) |
NZ (1) | NZ541596A (zh) |
WO (1) | WO2004074322A1 (zh) |
ZA (1) | ZA200506516B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107108717A (zh) * | 2015-05-20 | 2017-08-29 | 广州市香雪制药股份有限公司 | 一种可溶且稳定的异质二聚tcr |
WO2019057122A1 (en) * | 2017-09-22 | 2019-03-28 | Wuxi Biologics (Shanghai) Co., Ltd. | NEW BISPECIFIC POLYPEPTIDE COMPLEXES |
CN111433222A (zh) * | 2017-10-12 | 2020-07-17 | 得克萨斯大学体系董事会 | 用于免疫疗法的t细胞受体 |
CN112251452A (zh) * | 2019-10-22 | 2021-01-22 | 上海斯丹赛生物技术有限公司 | Til/tcr-t细胞治疗平台 |
WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
CN113646426A (zh) * | 2019-04-04 | 2021-11-12 | 上海医药集团股份有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
US11365254B2 (en) | 2017-09-22 | 2022-06-21 | WuXi Biologics Ireland Limited | Bispecific CD3/CD19 polypeptide complexes |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ531208A (en) * | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
US20060095211A1 (en) * | 2003-12-05 | 2006-05-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for modulating a cell mediated immune response |
US20060047437A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for heightening an immune response |
US20060116824A1 (en) * | 2004-12-01 | 2006-06-01 | Ishikawa Muriel Y | System and method for modulating a humoral immune response |
US20060047436A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for magnifying an immune response |
US20060047435A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to augmenting an immune system |
US20060182742A1 (en) * | 2004-08-24 | 2006-08-17 | Ishikawa Muriel Y | System and method for magnifying a humoral immune response |
US20060047433A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to enhancing an immune system |
US20060047434A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to improving an immune system |
GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
GB0411773D0 (en) * | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
DE602005022595D1 (de) * | 2004-06-29 | 2010-09-09 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
US20070265818A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for heightening cell-mediated immune response |
US20060047439A1 (en) * | 2004-08-24 | 2006-03-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for improving a humoral immune response |
US20070207492A1 (en) * | 2004-08-24 | 2007-09-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to adjust a humoral immune response |
US20070198196A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to ameliorating an immune system |
US20070196362A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to bolster an immune response |
US20070265819A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for improving cell-mediated immune response |
AU2005291039A1 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
GB0514779D0 (en) * | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
CA2626525C (en) | 2005-10-18 | 2020-03-10 | National Jewish Medical And Research Center | Conditionally immortalized long-term stem cells and methods of making and using such cells |
WO2007131092A2 (en) * | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
JP5602625B2 (ja) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | 結合物質のディスプレイ |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
IL287311B2 (en) | 2008-05-16 | 2024-06-01 | Taiga Biotechnologies Inc | Antibodies and processes for their preparation |
ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
GB2483810B (en) | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
DK2387627T3 (en) | 2009-01-15 | 2016-07-04 | Adaptive Biotechnologies Corp | Adaptive immunity profiling and methods for producing monoclonal antibodies |
EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
MX2011013417A (es) | 2009-06-25 | 2012-03-29 | Amgen Inc | Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero. |
CA2765949C (en) | 2009-06-25 | 2016-03-29 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
AU2012325791B2 (en) | 2011-10-21 | 2018-04-05 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
EP2788509B1 (en) | 2011-12-09 | 2018-07-11 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP3372694A1 (en) | 2012-03-05 | 2018-09-12 | Adaptive Biotechnologies Corporation | Determining paired immune receptor chains from frequency matched subunits |
US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
AU2013292330B2 (en) | 2012-07-20 | 2018-07-12 | Htyr Acquisition Llc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
EP2904111B1 (en) | 2012-10-01 | 2017-12-06 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
TWI775117B (zh) | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二) |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
US10023625B2 (en) | 2013-11-22 | 2018-07-17 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human T cell receptors |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
AU2015227054A1 (en) | 2014-03-05 | 2016-09-22 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
SG10201906461SA (en) * | 2014-03-05 | 2019-09-27 | Ucl Business Plc | Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
WO2016069886A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corporation | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
JP6415716B2 (ja) * | 2014-11-07 | 2018-10-31 | グアンドン シャンスエ ライフ サイエンス, リミテッド. | 可溶性のヘテロ二量体t細胞受容体およびその製法と使用 |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
AU2015353581A1 (en) | 2014-11-25 | 2017-06-15 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
EP3262196B1 (en) | 2015-02-24 | 2020-12-09 | Adaptive Biotechnologies Corp. | Method for determining hla status using immune repertoire sequencing |
HUE063627T2 (hu) | 2015-03-27 | 2024-01-28 | Immatics Biotechnologies Gmbh | Új peptidek és peptidkombináció többféle tumor elleni immunterápiában |
GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
AU2016242967B2 (en) | 2015-04-01 | 2021-07-01 | Adaptive Biotechnologies Corp. | Method of identifying human compatible T cell receptors specific for an antigenic target |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
CN108026154B (zh) | 2015-07-01 | 2022-03-08 | 伊玛提克斯生物技术有限公司 | 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物 |
SG10202001668PA (en) | 2015-07-06 | 2020-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
GB201516277D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR libraries |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
CN116731156A (zh) | 2016-03-16 | 2023-09-12 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的转染t细胞和t细胞受体 |
LT3430037T (lt) | 2016-03-16 | 2022-12-12 | Immatics Biotechnologies Gmbh | Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją |
BR112018070067A2 (pt) | 2016-04-06 | 2019-02-12 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso em imunoterapia contra lma e outros cânceres |
BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
IL262144B2 (en) * | 2016-04-08 | 2024-04-01 | Immunocore Ltd | T cell receptors |
KR102523449B1 (ko) * | 2016-04-08 | 2023-04-19 | 어댑티뮨 리미티드 | T 세포 수용체 |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
RU2766119C2 (ru) | 2016-06-02 | 2022-02-08 | Иммунокор Лимитед | Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
AU2017367730A1 (en) | 2016-12-02 | 2019-06-06 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
TWI796314B (zh) | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
TW201835100A (zh) | 2017-02-06 | 2018-10-01 | 國立研究開發法人國立癌症研究中心 | 新穎t細胞受體 |
ES2965475T3 (es) | 2017-02-12 | 2024-04-15 | Biontech Us Inc | Métodos y composiciones basados en HLA y usos de los mismos |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018189148A1 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
CN111548404A (zh) | 2017-04-10 | 2020-08-18 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
MX2019012398A (es) | 2017-04-18 | 2020-09-25 | Broad Inst Inc | Composiciones para detectar secreciones y metodos de uso. |
GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
CR20200059A (es) | 2017-07-07 | 2020-06-01 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres |
US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
CA3035209A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
CN111511388A (zh) | 2017-09-21 | 2020-08-07 | 博德研究所 | 用于靶向核酸编辑的***、方法和组合物 |
WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
CA3078472A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
EP3714041A1 (en) | 2017-11-22 | 2020-09-30 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
WO2019113385A1 (en) * | 2017-12-07 | 2019-06-13 | Janux Therapeutics, Inc. | Modified t cell receptors |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
US20210041435A1 (en) * | 2018-01-31 | 2021-02-11 | Tohoku University | Method for regulating antigen-specific mhc expression |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
JP7236543B2 (ja) | 2018-12-21 | 2023-03-09 | ビオンテック ユーエス インコーポレイテッド | Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
CN113748202B (zh) | 2019-03-01 | 2024-07-16 | 艾欧凡斯生物治疗公司 | 由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途 |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US20220306720A1 (en) | 2019-09-06 | 2022-09-29 | Eli Lilly And Company | Proteins comprising t-cell receptor constant domains |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
WO2021096868A1 (en) | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
WO2022087458A1 (en) | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的hla展示肽 |
WO2022187280A1 (en) | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
WO2023187127A1 (en) | 2022-03-31 | 2023-10-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
WO2024047642A1 (en) * | 2022-08-30 | 2024-03-07 | Clonal Ltd | Methods for detection of ovarian cancer |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
WO1996021028A2 (en) * | 1995-01-03 | 1996-07-11 | Procept, Inc. | Soluble heterodimeric t cell receptors and their antibodies |
CN1249229C (zh) * | 1998-05-19 | 2006-04-05 | 阿维德克斯有限公司 | 可溶性t细胞受体 |
NZ531208A (en) * | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
-
2003
- 2003-02-22 GB GBGB0304068.0A patent/GB0304068D0/en not_active Ceased
- 2003-07-09 EP EP03815958A patent/EP1594896B1/en not_active Expired - Lifetime
- 2003-07-09 DE DE60319745T patent/DE60319745T2/de not_active Expired - Lifetime
- 2003-07-09 WO PCT/GB2003/002986 patent/WO2004074322A1/en active IP Right Grant
- 2003-07-09 AU AU2003254443A patent/AU2003254443B2/en not_active Expired
- 2003-07-09 CA CA2516702A patent/CA2516702C/en not_active Expired - Lifetime
- 2003-07-09 AT AT03815958T patent/ATE388964T1/de not_active IP Right Cessation
- 2003-07-09 US US10/544,448 patent/US7666604B2/en active Active
- 2003-07-09 CN CNB03826014XA patent/CN100528897C/zh not_active Expired - Lifetime
- 2003-07-09 JP JP2004568435A patent/JP4478034B2/ja not_active Expired - Lifetime
- 2003-07-09 NZ NZ541596A patent/NZ541596A/en not_active IP Right Cessation
-
2005
- 2005-08-15 ZA ZA200506516A patent/ZA200506516B/en unknown
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107108717A (zh) * | 2015-05-20 | 2017-08-29 | 广州市香雪制药股份有限公司 | 一种可溶且稳定的异质二聚tcr |
CN107108717B (zh) * | 2015-05-20 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种可溶且稳定的异质二聚tcr |
WO2019057122A1 (en) * | 2017-09-22 | 2019-03-28 | Wuxi Biologics (Shanghai) Co., Ltd. | NEW BISPECIFIC POLYPEPTIDE COMPLEXES |
US11365254B2 (en) | 2017-09-22 | 2022-06-21 | WuXi Biologics Ireland Limited | Bispecific CD3/CD19 polypeptide complexes |
US11845796B2 (en) | 2017-09-22 | 2023-12-19 | WuXi Biologics Ireland Limited | Bispecific polypeptide complexes |
CN111433222A (zh) * | 2017-10-12 | 2020-07-17 | 得克萨斯大学体系董事会 | 用于免疫疗法的t细胞受体 |
CN113646426A (zh) * | 2019-04-04 | 2021-11-12 | 上海医药集团股份有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
CN112251452A (zh) * | 2019-10-22 | 2021-01-22 | 上海斯丹赛生物技术有限公司 | Til/tcr-t细胞治疗平台 |
WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
Also Published As
Publication number | Publication date |
---|---|
AU2003254443A1 (en) | 2004-09-09 |
JP2007527191A (ja) | 2007-09-27 |
WO2004074322A1 (en) | 2004-09-02 |
JP4478034B2 (ja) | 2010-06-09 |
US7666604B2 (en) | 2010-02-23 |
EP1594896A1 (en) | 2005-11-16 |
CA2516702C (en) | 2012-11-27 |
EP1594896B1 (en) | 2008-03-12 |
NZ541596A (en) | 2008-05-30 |
DE60319745T2 (de) | 2009-04-23 |
DE60319745D1 (de) | 2008-04-24 |
CA2516702A1 (en) | 2004-09-02 |
US20070082362A1 (en) | 2007-04-12 |
GB0304068D0 (en) | 2003-03-26 |
CN100528897C (zh) | 2009-08-19 |
ATE388964T1 (de) | 2008-03-15 |
AU2003254443B2 (en) | 2009-03-26 |
ZA200506516B (en) | 2006-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100528897C (zh) | 修饰的可溶性t细胞受体 | |
CN1561343B (zh) | 可溶性t细胞受体 | |
US20220213167A1 (en) | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof | |
CN105873945B (zh) | 工程化的高亲和力人类t细胞受体 | |
CN111148756A (zh) | T细胞受体 | |
CN109311945A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
CN108697776A (zh) | 在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法 | |
AU2018281316A1 (en) | Expression of novel cell tags | |
CN110177564A (zh) | 多价的调节t细胞调节剂 | |
US11672873B1 (en) | Anti-B7-H4 antibodies and methods | |
CN106478808B (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
JP2022515330A (ja) | 多量体t細胞調節ポリペプチド及びその使用方法 | |
CN106478807B (zh) | 识别mage-a3的t细胞受体 | |
CN109563147A (zh) | T细胞受体 | |
CN106084036A (zh) | 识别prame抗原短肽的t细胞受体 | |
CN106279404A (zh) | 一种可溶且稳定的异质二聚tcr | |
CN106188274A (zh) | 识别rhamm抗原短肽的t细胞受体 | |
EP3216801B1 (en) | Soluble heterodimeric t cell receptor, and preparation method and use thereof | |
CN100338217C (zh) | 单链重组t细胞受体 | |
WO2022166904A1 (zh) | 一种识别hpv的t细胞受体 | |
WO2023241391A1 (zh) | 一种结合ssx2抗原的tcr分子及其应用 | |
CN116836260A (zh) | 一种识别mage-a4的t细胞受体及其编码序列和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1089452 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: AMERICAN RUO BRANCH CO., LTD. Free format text: FORMER OWNER: MEDIGENE LTD. Effective date: 20100730 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MEDIGENE LTD. Free format text: FORMER NAME: AVIDEKS CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Oxfordshire Patentee after: MEDIGENE Ltd. Address before: Oxfordshire Patentee before: Avidex Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100730 Address after: Oxfordshire Patentee after: IMMUNOCORE LTD. Address before: Oxfordshire Patentee before: Medigene Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1089452 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: ADAPTIMMUNE LTD. Effective date: 20140813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140813 Address after: Oxfordshire Patentee after: IMMUNOCORE LTD. Patentee after: ADAPTIMMUNE Ltd. Address before: Oxfordshire Patentee before: IMMUNOCORE LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090819 |